CompletedPhase 1NCT03431480
Safety of Autologous Cord Blood Cells in HLHS Patients During Norwood Heart Surgery
Studying Hypoplastic left heart syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Murdoch Childrens Research Institute
- Principal Investigator
- Salvatore Pepe, DOMelbourne Children's Campus (incorporating The Royal Children's Hospital, Murdoch Children's Research Institute, the University of Melbourne Department of Paediatrics)
- Intervention
- Autologous Human Placental Cord Blood Mononuclear Cells(biological)
- Enrollment
- 10 enrolled
- Eligibility
- All sexes
- Timeline
- 2018 – 2022
Study locations (1)
- Royal Children's Hospital, Melbourne, Victoria, Australia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03431480 on ClinicalTrials.govOther trials for Hypoplastic left heart syndrome
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNANCT06342999Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart SyndromeMauro H. Schenone
- ACTIVE NOT RECRUITINGPHASE2NCT04925024Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS): A Phase IIb Clinical Trial.Longeveron Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT03779711Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart SyndromeTimothy J Nelson, MD, PhD
- RECRUITINGPHASE3NCT02781922Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial)Metcela Inc.
- RECRUITINGNCT02852031National Collaborative to Improve Care of Children With Complex Congenital Heart DiseaseChildren's Hospital Medical Center, Cincinnati